Precision BioSciences to meet with FDA after touting allogeneic CAR-T win
Precision BioSciences is now touting new data from a Phase I/II trial, saying that it has identified a dosing regimen that it believes will allow the North Carolina biotech to move its CAR-T into a mid-stage study.
Precision on Wednesday shared updated data for azercabtagene zapreleucel (azer-cel), the biotech’s lead candidate and allogeneic CAR-T therapy that targets CD19. It reported a 58% overall response rate and 41% complete response rate in a Phase I/IIa trial with 61 patients with non-Hodgkin lymphoma, across multiple doses and lymphodepletion regimens, as of May 30.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.